Lipocomb (Ezetimibe, Rosuvastatin Zinc)

The combination contains ezetimibe, which blocks the NPC1L1 transporter in the small intestine, preventing dietary and biliary cholesterol from being absorbed. Rosuvastatin inhibits HMG‑CoA reductase, the enzyme responsible for hepatic cholesterol synthesis. Together they reduce the amount of cholesterol entering the bloodstream and increase removal of LDL particles.

The dosage of Lipocomb is individualized by the prescribing healthcare professional based on the patient’s lipid profile, cardiovascular risk and tolerance. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted during therapy according to laboratory results and clinical response.

Safety of Lipocomb in pregnancy and lactation has not been established. Because rosuvastatin is classified as contraindicated in pregnancy and ezetimibe lacks sufficient data, the product should generally be avoided in pregnant or nursing women unless the potential benefit justifies the potential risk.

To request Lipocomb, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any temperature requirements) and the necessary import documentation.

Lipocomb combines a cholesterol absorption inhibitor with a high‑potency statin, offering greater LDL‑cholesterol reduction than either agent alone. Compared with monotherapy, the combination can achieve target lipid levels more rapidly and may be useful for patients who do not reach goals with a single drug, while maintaining a safety profile comparable to standard statin therapy.

Lipocomb tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture, heat and direct sunlight. Do not store in bathrooms or other humid environments, and keep out of reach of children.

Lipocomb is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water. Do not crush, chew or split the tablet unless specifically instructed, as this could affect the drug’s absorption.

The most serious adverse events include rhabdomyolysis (severe muscle breakdown), significant liver enzyme elevations indicating hepatotoxicity, and severe allergic reactions such as anaphylaxis. Patients should promptly report unexplained muscle pain, weakness, dark urine, jaundice, or signs of hypersensitivity to their healthcare provider.

Lipocomb is contraindicated in individuals with active liver disease, unexplained persistent elevations of hepatic transaminases, known hypersensitivity to ezetimibe, rosuvastatin or any excipients, and in pregnant or nursing women. Caution is also advised for patients with severe renal impairment or those taking interacting medications that could increase statin exposure.